Rhumbline Advisers decreased its position in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,029 shares of the health services provider’s stock after selling 999 shares during the period. Rhumbline Advisers owned approximately 0.30% of Amedisys worth $7,136,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of AMED. Mackenzie Financial Corp lifted its holdings in Amedisys by 67.7% in the first quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock valued at $164,844,000 after buying an additional 386,411 shares during the period. Millennium Management LLC raised its holdings in shares of Amedisys by 222.6% during the fourth quarter. Millennium Management LLC now owns 478,081 shares of the health services provider’s stock valued at $39,939,000 after purchasing an additional 329,891 shares during the period. Norges Bank acquired a new position in shares of Amedisys during the fourth quarter valued at about $26,014,000. Deutsche Bank AG raised its holdings in shares of Amedisys by 3,024.7% during the fourth quarter. Deutsche Bank AG now owns 273,787 shares of the health services provider’s stock valued at $22,872,000 after purchasing an additional 265,025 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Amedisys by 3.7% during the first quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock valued at $671,378,000 after purchasing an additional 138,484 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.
Wall Street Analysts Forecast Growth
AMED has been the topic of several research reports. Cantor Fitzgerald upped their price objective on shares of Amedisys from $91.00 to $100.00 in a report on Tuesday, June 6th. Benchmark lowered shares of Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, June 27th. Truist Financial upped their price objective on shares of Amedisys from $97.00 to $101.00 in a report on Tuesday, June 27th. TD Cowen boosted their target price on shares of Amedisys from $84.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, July 31st. Finally, StockNews.com began coverage on shares of Amedisys in a research report on Tuesday. They set a “buy” rating for the company. Ten analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $109.60.
Amedisys Stock Up 0.0 %
Amedisys stock opened at $93.87 on Wednesday. Amedisys, Inc. has a twelve month low of $69.36 and a twelve month high of $126.81. The firm has a 50 day moving average price of $91.91 and a 200-day moving average price of $85.30. The company has a market capitalization of $3.06 billion, a P/E ratio of 1,339.48, a P/E/G ratio of 2.56 and a beta of 1.00. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.35.
Amedisys (NASDAQ:AMED – Get Free Report) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $1.37 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.28. The company had revenue of $552.97 million for the quarter, compared to analysts’ expectations of $568.18 million. Amedisys had a net margin of 0.10% and a return on equity of 14.00%. Amedisys’s revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.47 EPS. As a group, equities analysts predict that Amedisys, Inc. will post 4.42 EPS for the current year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
- Five stocks we like better than Amedisys
- Dividend Payout Ratio Calculator
- 5 Ways to Play Retail that will Profit in 2023
- 5 Top Rated Dividend Stocks to Consider
- This Is Why It’s Not Too Late For You To Buy Meta Stock
- How to Find Cloud Software Company Stocks to Trade and Invest
- Why Analysts Say GE’s Healthcare Spinoff Has $20 Upside
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.
